Dupilumab for treating bullous pemphigoid

Dupilumab is currently in phase II/III development for adult patients with bullous pemphigoid (BP). BP is the most common form of blistering disorders of the skin. The first symptom of BP is usually redness and itching of the skin. BP primarily affects older people, with an average age around 80 years old. The burden of disease in the older population is considerable. BP is commonly treated with steroids (oral or creams). However, these can have side effects such as high blood pressure, weakened bones and increased infection rates, which is a concern, especially amongst frail, older people with multiple co-morbidities.